Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
46 Chronic Kidney Disease Trials near Miami, FL
Power is an online platform that helps thousands of Chronic Kidney Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerBI 690517 + Empagliflozin for Chronic Kidney Disease
Miami, FloridaThis study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart disease.
This study has 2 parts. In the first part, participants get empagliflozin or placebo matching BI 690517 for at least 6 weeks. Participants continue taking ACEi or ARB throughout the study if such treatments are indicated. In the second part, participants are divided into 2 groups by chance. One group takes BI 690517 tablets and the other group takes placebo tablets. Placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants take 1 tablet once a day in addition to empagliflozin for the duration of the study.
The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 4 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:High Potassium, Liver Cirrhosis, Dialysis, Others
Must Not Be Taking:MRAs, Dual RAS Inhibitors
11000 Participants Needed
Finerenone for Chronic Kidney Disease in Type 1 Diabetes
Miami, FloridaThis trial is testing finerenone, a drug that helps protect kidneys and hearts, in people with chronic kidney disease and type 1 diabetes. The study aims to see how well finerenone works in slowing down kidney damage. Researchers will also monitor the safety of the drug by tracking any medical issues participants experience. Finerenone has been shown to delay the progression of chronic kidney disease and reduce cardiovascular events in patients with diabetic kidney disease, particularly type 2 diabetes.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
220 Participants Needed
Primary Objective:
Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).
Secondary Objectives:
* Evaluate the safety profile of Hectorol® capsules versus Rocaltrol® (calcitriol) capsules.
* Determine the pharmacokinetic profile of 1,25-dihydroxyvitamin D2 after administration of Hectorol®.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:5 - 18
Sex:All
84 Participants Needed
AION-301 for Chronic Kidney Disease
Miami, FloridaThe goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression. The main questions it aims to answer are:
* Do participants have medical problems (adverse events) after receiving two infusions of AION-301?
* Do participants feel better (have reduced and/or delayed CKD symptoms)?
* To learn about how AION-301 works in participants with CKD?
Researchers will compare AION-301 to a placebo (a look-alike substance that contains no drug) to see if AION-301 works to treat Stage 3 CKD.
Participants will:
* Receive two infusions of AION-301 or placebo on two separate days (Day 0 and Day 4).
* Receive oral vitamins at the clinic and to take at home for 90 days.
* Visit the clinic for a minimum of 9 times, over 6 months for checkups and tests, but could be up to 12 times, over 24 months for checkups and tests.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:35 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Transplant, Malignancy, Autoimmune, Others
Must Be Taking:RAAS Blockers, SGLT2 Inhibitors
36 Participants Needed
Lorundrostat + Dapagliflozin for Kidney Disease
Coconut Grove, FloridaThis is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor \[ASI\]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB). Subjects will be at least 18 years old with hypertension, and mild to severe CKD with albuminuria at the Screening Visit.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
60 Participants Needed
AZD4144 for Cardiovascular and Kidney Disease
Miami, FloridaThe purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Malignancy, Recent MI, Active Infection, Others
28 Participants Needed
This trial is testing a new medicine called CagriSema to see if it can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and who are overweight or obese. The study will compare CagriSema to two other medicines.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Hereditary Kidney Diseases, Dialysis, Others
Must Be Taking:Ace Inhibitors, Arbs
618 Participants Needed
Ziltivekimab for Cardiovascular Disease
Miami, FloridaThis trial is testing whether ziltivekimab can lower the risk of heart attacks and strokes in people with heart disease, kidney disease, and inflammation. Participants will inject the medicine regularly. The study aims to see if reducing inflammation can help prevent serious heart problems.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active Infection, Recent Heart Attack, Recent Stroke, Others
6200 Participants Needed
Renal Denervation for High Blood Pressure
Miami, FloridaThis trial is studying the safety and effectiveness of a device called the Symplicity Spyral system, which helps lower blood pressure by calming overactive nerves in the kidneys. It includes patients who have already received this treatment. The Symplicity Spyral system is part of a series of treatments, with earlier versions showing significant blood pressure reductions in patients with resistant hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Renal Anatomy, Oxygen Support, Diabetes, Others
1400 Participants Needed
Retatrutide for Obesity
Miami, FloridaThe main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+
Sex:All
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Recent Heart Attack, Others
10000 Participants Needed
Baxdrostat + Dapagliflozin for Chronic Kidney Disease
Coral Gables, FloridaThe purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN.
This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone.
Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 6-weeks (approximately), where reassessment of GFR will occur for the primary efficacy endpoint.
In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Heart Failure, Others
Must Be Taking:ACE Inhibitors, ARBs
2500 Participants Needed
This trial is testing a medication called paricalcitol, which is taken by mouth, in young children with severe kidney disease and hormone imbalance. The goal is to see if it is safe and effective in balancing their hormone levels. Paricalcitol has been shown to be effective in reducing calcium and phosphorus levels in patients with kidney issues.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:0 - 9
Sex:All
Key Eligibility Criteria
Disqualifiers:Kidney Transplant, Parathyroidectomy, Others
Must Be Taking:VDRAs
16 Participants Needed
Ravulizumab for Kidney Disease
Miami, FloridaThe primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Rapid Glomerulonephritis, Secondary IgAN, Others
Must Be Taking:RASI, SGLT2I
510 Participants Needed
Zilebesiran for High Blood Pressure
New Orleans, LouisianaThe purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
375 Participants Needed
BMS-986278 for Kidney Failure
Miami, FloridaThe purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278. This study plans to use a staged design based on RI severity.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 84
Sex:All
Key Eligibility Criteria
Disqualifiers:Significant Medical Condition, Pregnancy, Others
32 Participants Needed
Anti-Factor XI Monoclonal Antibody for Kidney Failure
Coral Gables, FloridaThis trial is testing MK-2060, a medicine that blocks a blood protein, on patients with severe kidney disease. The goal is to see if it can prevent clots and keep the treatment method effective for a longer period.
Trial Details
Trial Status:Active Not Recruiting
Age:18+
Sex:All
506 Participants Needed
PLS240 for Secondary Hyperparathyroidism
Coral Gables, FloridaThis trial is testing a medication called PLS240 to help people with severe kidney disease who are on dialysis and have a related gland problem. The study will check if PLS240 can safely manage their condition by controlling certain hormones and minerals in their blood. Patients will be monitored over time.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 80
Sex:All
362 Participants Needed
HAV vs AVF for Kidney Failure
Miami, FloridaThe goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD).
Participants will be stratified by location of the vascular access (forearm versus upper arm) and by type of AVF creation procedure planned by the surgeon at randomization (1-stage AVF versus 2-stage AVF). The comparator is an upper extremity arterio-venous fistula (AVF) for HD access surgically created per the institution's Standard of Care (SoC).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Male, Pregnancy, Cancer, Others
Must Not Be Taking:Aspirin, Antiplatelet Therapy, Others
150 Participants Needed
CSL300 for Kidney Failure
Miami, FloridaThis trial is testing CSL300, a new treatment, to see if it helps people with heart disease or diabetes who are on dialysis. The study aims to find the right dose and check if it improves heart health by reducing inflammation.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Abnormal LFTs, Life-threatening Disease, Others
Must Not Be Taking:Immunosuppressants
2310 Participants Needed
Balcinrenone + Dapagliflozin for Chronic Kidney Disease
Miami Lakes, FloridaThe purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD.
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
324 Participants Needed
DISC-0974 for Anemia in Chronic Kidney Disease
Miami, FloridaThis trial tests a new drug called DISC-0974 in adults with chronic kidney disease who are not on dialysis and have anemia. It aims to see if the drug is safe and how it behaves in and affects the body.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Dialysis, Hemolytic Anemia, Hemochromatosis, Others
Must Not Be Taking:Oral Iron, ESAs, IV Iron
50 Participants Needed
Orforglipron for Type 2 Diabetes and Obesity
Hialeah, FloridaThis trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
2749 Participants Needed
BI 764198 for Focal Segmental Glomerulosclerosis
Miami, FloridaThis trial tests if the medicine BI 764198 can improve kidney health in adults with a specific kidney disease called FSGS. Participants take the medicine regularly for a few months. Their kidney health is checked through urine samples and regular health check-ups.
Trial Details
Trial Status:Active Not Recruiting
Age:18 - 75
Sex:All
67 Participants Needed
Sirogen for Arteriovenous Fistula Outcomes
Miami, FloridaThe primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:65+
Sex:All
136 Participants Needed
PLS240 for Secondary Hyperparathyroidism
South Miami, FloridaThis trial is testing a medication called PLS240 to help people with severe kidney disease who are on dialysis and have a related gland problem. The study will check if PLS240 can safely manage their condition by controlling certain hormones and minerals in their blood. Patients will be monitored over time.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 80
Sex:All
412 Participants Needed
EndoAVF Creation for Chronic Kidney Failure
Miami, FloridaThis trial studies the BD® WavelinQ™ EndoAVF System, a device that creates a connection between an artery and a vein. It is designed for patients who need dialysis. The device helps make a new pathway for blood flow, which is essential for the dialysis process.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Hypercoagulable State, Bleeding Diathesis, Active Drug Abuse, Others
280 Participants Needed
NNC0519-0130 for Kidney Disease
Hollywood, FloridaThe study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Lupus Nephritis, Dialysis, Others
Must Be Taking:Ace Inhibitors, Arbs
465 Participants Needed
Finerenone for Chronic Kidney Disease
Hollywood, FloridaThis trial is testing whether adding finerenone to existing treatments can help children with chronic kidney disease and proteinuria. The study will measure if finerenone can reduce the amount of protein in their urine and improve kidney function. Children will continue their usual medications and be monitored through various health checks and tests. Finerenone has been shown to delay the progression of chronic kidney disease.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Planned Urological Surgery, Nephrotic Syndrome, Others
Must Be Taking:ACEI, ARB
219 Participants Needed
Finerenone for Pediatric Chronic Kidney Disease
Hollywood, FloridaThis trial tests finerenone, a new medication added to existing treatments, to help children with chronic kidney disease (CKD) and proteinuria. It aims to see if finerenone can better control kidney function and reduce protein in the urine. The study will monitor safety and effectiveness over several months. Finerenone has been shown to delay the progression of chronic kidney disease.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:1 - 18
Sex:All
Key Eligibility Criteria
Disqualifiers:Planned Urological Surgery, Renal Transplantation, Hypertension, Others
Must Be Taking:ACEI, ARB
100 Participants Needed
TOUR006 for Chronic Kidney Disease
Pembroke Pines, FloridaThis study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
143 Participants Needed
Page 1 of 2+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Chronic Kidney Disease clinical trials in Miami, FL pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Chronic Kidney Disease clinical trials in Miami, FL work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Chronic Kidney Disease trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL for Chronic Kidney Disease is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Chronic Kidney Disease medical study in Miami, FL ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Chronic Kidney Disease clinical trials in Miami, FL ?
Most recently, we added MK-5684 for Kidney Disease, Baxdrostat + Dapagliflozin for Chronic Kidney Disease and High Blood Pressure and Access Program for Kidney Transplant to the Power online platform.